A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk, or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection (SOLAR 003)
SOLAR 003 focuses on determining the safety and effectiveness of Copper Cu 64 PSMA I&T Injection as an imaging agent in the staging of men with newly diagnosed prostate cancer in those electing to undergo radical prostatectomy with extended pelvic lymph node dissection.
Principal Investigator: Dr. Medhat Osman
Study Coordinator: Brittany Minor
This study is now enrolling patients.
To learn more about the SOLAR STAGE 003 trial and how you can join contact our research office at (314) 289-7690.
This studies are funded by the Foundation through the sponsor CURIUM
Principal Investigator: Dr. Medhat Osman
Study Coordinator: Brittany Minor
This study is now enrolling patients.
To learn more about the SOLAR STAGE 003 trial and how you can join contact our research office at (314) 289-7690.
This studies are funded by the Foundation through the sponsor CURIUM